Previous researches on CKI were mainly focused on the antitumor effect, including targeting Prdxs/ROS/Trx1 axis to inhibit acute myeloid leukemia,19 targeting TRPV1/ERK signaling to suppress sarcoma,13 targeting Wnt/β‐catenin pathway to inhibit breast cancer,17 and targeting TNFR1‐mediated NF‐κB signaling in tumor‐associated macrophages to remodel HCC microenvironment.21 The gene discussed is NFKB1; the disease is acute myeloid leukemia.